Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03623464 · ClinicalTrials.gov registry record · NA

RCT of Mobile Apps & FitBit v. Usual Care

A NA study of Pancreatic Cancer and Gastric Cancer, sponsored by Weill Medical College of Cornell University.

Active
Registry status
NA
Development phase
107
Enrollment target
1
Study location

NCT03623464 is a NA study of Pancreatic Cancer and Gastric Cancer that is active but no longer recruiting, run by Weill Medical College of Cornell University. The registered enrollment target is 107 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (73% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03623464, a NA study of Pancreatic Cancer and Gastric Cancer, is active but no longer recruiting, sponsored by Weill Medical College of Cornell University.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
107 participants
Enrollment target
1
Study location

Study Summary

This is a randomized clinical trial to evaluate the use of mobile devices in preventing readmission in patients undergoing major GI cancer operations.

Interventions

  • OTHER Standard of care
  • OTHER Mobile health application and Fitbit + standard of care

Study Locations (1)

New York

  • Weill Cornell Medicine- New York Presbyterian - New York

Trial Details

FieldValue
Enrollment Target 107 participants
Start Date 2017-05-31
Est. Completion 2026-06
Phase NA

What the Registry Record Tells You About NCT03623464

The ClinicalTrials.gov registry entry for NCT03623464 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (73% lower). The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which Standard of care is the first listed.

NCT03623464 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT03623464 about?

NCT03623464 is a clinical study titled "RCT of Mobile Apps & FitBit v. Usual Care". This is a randomized clinical trial to evaluate the use of mobile devices in preventing readmission in patients undergoing major GI cancer operations.

What is the current status of trial NCT03623464?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 107 participants. The study started on 2017-05-31. Estimated completion is 2026-06.

What conditions does trial NCT03623464 study?

This clinical trial studies the following conditions: Pancreatic Cancer, Gastric Cancer, Colon Cancer, Rectal Cancer, Hepatic Cancer.

What interventions are being tested in trial NCT03623464?

The interventions under investigation include: Standard of care (OTHER), Mobile health application and Fitbit + standard of care (OTHER).

Who is sponsoring clinical trial NCT03623464?

This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03623464 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.